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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To assess the diagnostic accuracy of sentinel lymph node biopsy in the identification of lymph node involvement in patients with early
stage cervical cancer (Stage IA2 to IIA).
We will first explore the impact of major factors for heterogeneity such as tumour size, FIGO stage and timing between application,
detection of tracers, tracer substance used, surgical approach, experience of the operator and use of histological ultra-staging techniques.
Then, we may consider other factors such as previous treatment to the cervix (including conisation), patient age and body mass index,
as these have previously been suggested as possible factors associated with success or failure of sentinel node identification (Sinno 2014;
Tanner 2015; Wuntakal 2015).
B A C K G R O U N D
Target condition being diagnosed
Cervical cancer is the fourth most common cancer in women,
and the seventh overall, with an estimated 528,000 new cases and
266,000 deaths attributed to cervical cancer worldwide in 2012,
accounting for 7.5% of all female cancer deaths (GLOBOCAN
2012). A large majority (around 85%) of the global burden oc-
curs in less-developed regions, where it accounts for almost 12%
of all female cancers. Cervical cancer remains the most common
cancer in women in Eastern and Middle Africa. This fact reflects
the differences in the availability of effective Human Papilloma
Virus (HPV) vaccination and cervical screening programmes as
well as effective treatments. In Europe, approximately 60% of
women with cervical cancer are alive five years after diagnosis
(EUROCARE 5a).
Cervical cancer is staged according to the FIGO system (Benedet
2003), which is based on findings from clinical examination (Table
1). Stage I disease is confined to the cervix. This is subdivided into
stage IA and IB. Stage IA can only be seen with a microscope,
while IB can usually be seen with the naked eye. Stage IA is further
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divided into Stage IA1 and stage IA2. Stage IA1 means the cancer
has invaded less than 3 mm into the cervical tissue and it is less
than 7 mm wide. Stage IA2 means that the cancer has invaded
between 3 mm and 5 mm deep but is still less than 7 mm wide. If
the cancer is bigger than Stage IA2, but still confined to the cervix,
it would be classified as stage IB. Stage IB again can be divided
into IB1 and IB2 where IB1 represents cancers that are less than
4 cm across while IB2 are tumours larger than 4 cm.
For Stage II disease, the tumour has spread to the upper part of
the vagina (stage IIA) or to the tissues around the cervix, but
not reaching the pelvic side wall (stage IIB). Stage III represents
disease that has reached the lower part of the vagina (IIIA) or
the pelvic side wall (IIIB) and Stage IV represents disease that
has spread to the other organs such as the bladder or the bowel.
Although lymph node involvement does not contribute to the
FIGO staging, it is one of the most important factors in prognosis
and determining treatment. For early disease (stage IB to IIA),
about 95% of women can expect to be alive after five years (
Kim 2000). However, if the tumour had spread to the lymph
glands in the pelvis, the expected survival at five years drops to
about 78%. Furthermore, data suggest that extra-pelvic lymph
node metastases further impacts on survival (Kim 2000). In this
review, women with FIGO stage IA2 to IIA cervical cancer will be
the population of interest as this group of women would usually
be candidates for systematic pelvic lymphadenectomy as part of
the surgical treatment of their cervical cancers (Rationale).
Index test(s)
The detection of the sentinel node in cervical cancer involves
subepithelial injection of a radioactive tracer substance e.g.
99mTC (technetium) -labelled colloid, blue dye (e.g. Patent Blue
or methylene blue) or indocyanine green (ICG) into the cervix be-
fore the operation. The spread of the tracer substance wouldmimic
the cancer cells and follow the lymphatic drainage around the
cervix. The tracer substance would localise to the lymph nodes that
represent the first lymph nodes in the lymphatic chain to which
cancer cells would spread. If radioactive tracer substance is used,
the total radioactive dose varies between 10 MBq to 111 MBq,
depending on the time interval between injection and surgery
(Lantzsch 2001; Rhim 2002), and a scan to look at the lymphatic
system (lymphoscintigraphy) may be performed after injection of
the radioactive tracer to map the location of the sentinel lymph
nodes (Bats 2007; Darai 2007). Preoperative lymphoscintigraphy
gives some guidance to the surgeons with regard to the location of
the sentinel lymph nodes. If blue dye or ICG are used, the tracer
substance is injected into the cervix at the beginning of surgery.
Intraoperatively, blue dye stained lymph nodes can be visualised
after opening the retroperitoneum, and nodes with radioactive
uptake can be detected with a gamma camera. ICG is visualised
using near-infrared fluorescence (NIR) and can be detected trans-
peritoneally prior to opening the retroperitoneum. Lymph nodes
that are stained with ICG or blue dye or nodes and are radioactive
are then removed as sentinel lymph nodes (Schneider 2007). The
sentinel node is then submitted for histological analysis. Histolog-
ical analysis may include ultra-staging techniques to improve the
detection of smaller cancer cell deposits (Cibula 2012). If cancer
cells are present, the node is considered as positive. Intraopera-
tive frozen section histological analysis of sentinel lymph nodes
has previously been described. This technique, however, has been
shown to be less reliable for the diagnosis of lymph node metas-
tases than analysis of fixed histological specimens (Bats 2011).
Prospective and retrospective data suggest that sentinel lymph
node assessment can achieve a greater than 90% sensitivity and
100% specificity in predicting lymph node status in women with
cervical cancer (Cibula 2012; Kadkhodayan 2015; Lecuru 2011;
Selman 2008; Tax 2015; Wang 2015). However, if the procedure
only includes the injection of blue dye without the use of a radioac-
tive tracer or vice versa, the detection rate and sensitivity are signif-
icantly reduced when compared to the combined technique (Van
de Lande 2007). Currently, the technique of sentinel lymph node
detection ismainly confined to clinical trials, though reports of this
technique being incorporated into standard practice in early stage
disease are emerging (Devaja 2012; Gortzak-Uzan 2010; Niikura
2012; Wuntakal 2015). In clinical trials, regardless of the status of
the sentinel node, a systematic lymphadenectomy would still be
carried out in order to avoid wrong clinical management in the
case of a false-negative result. Ideally, if sentinel node assessment
is accurate, it can replace the need for a systematic lymphadenec-
tomy and its associated risks (see Rationale). However, in the sit-
uation where there is a false-negative result (i.e. when there were
positive lymph nodes but the sentinel lymph node was negative),
omission of a systematic lymphadenectomy would mean that the
positive lymph nodes would remain in the woman and she would
be falsely diagnosed as “lymph node negative”. This would lead to
omission of chemo-irradiation as part of her treatment and might
lead to a significant negative impact on her overall prognosis.
Role of the index test
The role of the index test is to predict accurately lymph node
metastases in women with early stage cervical cancer so that the
need for further treatment can be determined whilst the extent of
surgery can be reduced.
Clinical pathway
Clinical pathway for women with early stage cervical cancer (
Figure 1)
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Figure 1.
Alternative test(s)
Radiological Imaging techniques have been used to assess lymph
node status before primary surgery. These have the advantage of
being non-invasive, but their sensitivities appeared to be limited.
Computer tomography (CT) and magnetic resonance imaging
(MRI) rely on size and morphological criteria to recognise lymph
node metastasis, and small metastatic nodes may be missed (Boss
2000; Hricak 1993; Schneider 2007; Yang 2000). A systematic
review of 57 articles between 1985 and 2002 showed sensitivities
for lymph node involvement in women with cervical cancer for
MRI andCTof 60%and 43%, respectively (Bipat 2003). Positron
emission tomography (PET) gives functional imaging of cancer
cells. Used alone or in combination with CT, it has been applied
in the staging assessment of various gynaecological cancers. High
sensitivity and specificity in detection of para-aortic metastases in
advanced or recurrent cervical cancer have been reported (Rose
1999), but its role in predicting pelvic node involvement in early
disease of gynaecological cancers in general is still uncertain (Lai
2007). A meta-analysis involving 445 women with primary cer-
vical cancer in eight studies showed that the sensitivity of PET in
predicting lymph node status was 74.7% and the specificity was
97.6% (Selman 2008). The sensitivities for imaging techniques in
the detection of the sentinel nodes in cervical cancer are not high
enough to be clinically useful.
Rationale
For early disease (Stage I to Stage IIA), surgery is themost common
treatment method. In very early disease (IA1 and IA2), this can be
limited to removal of the part of the cervix affected by cancer or by
a simple, or standard hysterectomy (Bouchard-Fortier 2014). For
Stage IB disease or above, a radical hysterectomy which involves
a hysterectomy together with removal of tissues around the cervix
is the traditional treatment of choice and this may be either as an
open abdominal or as a key-hole operation (Kucukmetin 2013).
Radical hysterectomy may be followed by radiotherapy or a com-
bination of chemotherapy and radiotherapy for women with stage
IB to IIA cervical cancer, though the impact of this adjuvant treat-
ment on overall survival is thought to be limited (Rogers 2012).
For higher stages (Stage IIB or above), the main treatment would
be chemo-irradiation instead of surgery. Lymph node metastasis
has been found in less than 1% of FIGO Stage IA1 disease (Elliott
2000), but this increases to 9% in Stage IA2 disease (Takeshima
1999). As there is a higher chance of lymph node metastasis in
Stage IA2 or above, pelvic lymph node dissection forms part of
the standard treatment for Stage IA2 to IIA cervical cancer. The
current reference standard for determining lymph node spread
is by a systematic lymphadenectomy where all the lymph nodes
along the major vessels in the pelvis are removed for histological
assessment. However, such dissection is associated with potential
morbidities such as formation of lymphocysts and lymphoedema
in up to 20% of women (Ryan 2003), and the risk of these mor-
bidities may be significantly reduced if sentinel lymph node exci-
sionwere to replace systematic lymphadenectomy (Achouri 2013).
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Considering the low incidence of lymph node involvement, most
women, particularly those with very early disease, would have un-
dergone a systematic dissection, with its associated risks, unneces-
sarily. Furthermore, in situations where lymph nodes are histolog-
ically confirmed to be involved, chemo-irradiation would be of-
fered. In these patients, systematic node dissection is of uncertain
additional benefit. Therefore, different ways of assessing lymph
node involvement have been explored.
Imaging techniques such as CT scans, MRI and PET are non-
invasive methods that can be used to detect enlarged lymph nodes.
However, these methods cannot accurately determine whether the
enlarged nodes are due to cancer involvement or due to a reactive
response to local infection or an inflammatory response to the ma-
lignant lesion. Alternatively, the concept of sentinel node assess-
ment has been investigated. The sentinel lymph node is the first
lymph node to which the tumour cells would spread via the lym-
phatics. The histological status of the sentinel node is presumed
to be representative of all other lymph nodes draining the same
anatomical site: that is, if this sentinel node is negative histolog-
ically; the remaining lymph nodes draining the same region are
assumed to be also negative. Since there is a possibility for sentinel
node biopsy to replace a systematic lymphadenectomy in clinical
practice (whereas the various imaging techniques are unlikely to
do so), this review will concentrate on assessing the diagnostic ac-
curacy of sentinel node biopsy alone.
O B J E C T I V E S
To assess the diagnostic accuracy of sentinel lymph node biopsy
in the identification of lymph node involvement in patients with
early stage cervical cancer (Stage IA2 to IIA).
Secondary objectives
We will first explore the impact of major factors for heterogeneity
such as tumour size, FIGO stage and timing between application,
detection of tracers, tracer substance used, surgical approach, ex-
perience of the operator and use of histological ultra-staging tech-
niques. Then, wemay consider other factors such as previous treat-
ment to the cervix (including conisation), patient age and body
mass index, as these have previously been suggested as possible
factors associated with success or failure of sentinel node identifi-
cation (Sinno 2014; Tanner 2015; Wuntakal 2015).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Included studies may be either prospective or retrospective designs
comparing sentinel node biopsy with the reference standard. We
will exclude studies reporting insufficient data for accurate identi-
fication of the target population or for the construction of a two-
by-two table, and case-control studies. We will also exclude studies
with fewer than 10 cases.
Participants
Women diagnosed with early stage (IA2 to IIA) cervical cancer on
the basis of loop biopsy (for microscopic disease) or examination
under anaesthesia and biopsy with or without cystoscopy. We will
consider all settings and all ages in this review. We will include
studies that include at least 80% of women with early stage disease,
as it is expected that some studies will have small percentages of
women with Stage IIB, III and IV disease.
Index tests
Sentinel lymph node biopsy. Studies should specify the technique
used, including:
• whether radioactive tracer, blue dye, ICG or a combination
of these were used;
• technique of injection of tracer substance, including timing
of injection, amount of tracer used and location of injection;
• exact technique of detection of tracer substance (e.g.
whether a preoperative scintigram was done, whether the
intraoperative detection was done via an open, laparoscopic or
robotic approach and for studies which use ICG, which near-
infrared fluorescence (NIR) system was used to detect the lymph
node);
• definition of what is regarded as a sentinel node;
• the histological method of assessment of the sentinel node
including details of any ultra-staging techniques used.
A sentinel node should be defined as a lymph node sending a ra-
dioactive signal with an activity higher than 10-fold above back-
ground radiation level, a node that appears blue intraoperatively
or, in the case of ICG-NIR, a node that appears to fluoresce when
specialised near-infrared equipment is used for detection. The sen-
tinel node identified should be removed and submitted for histo-
logical examination with at least haematoxylin and eosin (H & E)
staining, including those at extra-pelvic sites. If the sentinel node
is found to be malignant by histological examination, it is defined
as a positive sentinel node. If a sentinel node is detected but histo-
logically did not show any malignancy, it may be subjected to ul-
tra-staging techniques. If no malignancy is detected in the lymph
node, it is defined as a negative node. Results of the studies need
to report whether sentinel nodes are detected unilaterally or bi-
laterally. If a sentinel node cannot be identified by the tracer sub-
stance used, then it is defined as ’failure to detect sentinel nodes’.
In the case of failure to detect sentinel nodes either unilaterally
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or bilaterally, the studies should report whether a side-specific or
bilateral systematic pelvic lymphadenectomy was undertaken.
In the situation where lymph node metastases is detected by sys-
tematic lymphadenectomy and not by a sentinel lymph node, it
should be specified whether the positive lymph nodes identified by
systematic lymphadenectomy are on the side that no sentinel node
was detected; or that a sentinel node was identified on that side
and was negative. We would take these situations into account in
conducting the analysis, as they may have important implications
on the true accuracy of the test.
Target conditions
Pelvic lymph node metastases in early stage cervical cancer (IA2
to IIA).
Reference standards
Systematic pelvic lymphadenectomy, laparoscopic or open, fol-
lowed by standard histological assessment of surgical specimen.
Systematic pelvic lymphadenectomy should include removal of all
the obturator, internal and external iliac and common iliac nodes,
with or without para-aortic nodes. The removed surgical speci-
men would be subjected to standard histological assessment with
at least H & E staining. If any of the removed nodes showed can-
cer metastasis histologically, the reference standard is considered
positive. Studies should specify how many lymph nodes at each of
the above sites were removed. Studies should also specify whether
the reference standard result is positive for one side or both sides
of the pelvis.
Search methods for identification of studies
Electronic searches
We will search the following electronic databases.
• MEDLINE (OvidSP) (1946-current)
• Embase (OvidSP) (1980-current)
We will use the search strategy specified in Appendix 1 to search
MEDLINE, which reflects the key concepts of the review to in-
clude recent reports that incorporate ICG-NIR technology: index
test (sentinel lymph node biopsy) AND target condition (pelvic
lymph node metastases in early stage cervical cancer). We will de-
sign a similarly structured search strategy using search terms ap-
propriate for Embase.
We will not apply language restrictions to the electronic searches
and we will arrange for translations, where possible, if relevant
studies are found in languages other than English.
Searching other resources
We will check the reference lists of all studies deemed to be rel-
evant from the electronic searches for additional potentially rele-
vant studies.
We will also search the following databases for related systematic
reviews, and we will check the reference lists of those that are
relevant for additional studies.
• DARE (Database of Abstracts of Reviews of Effects)
www.york.ac.uk/inst/crd/crddatabases.htm#DARE
• MEDION (Meta-Analyses van Diagnostisch Onderzoek)
www.mediondatabase.nl
• HTA Database (Health Technology Assessments Database)
www.york.ac.uk/inst/crd/crddatabases.htm#HTA
• ARIF (Aggressive Research Intelligence Facility)
www.arif.bham.ac.uk
We will use all studies identified as relevant as seeds in PubMed to
search for additional studies using the related articles feature.
We will also use the relevant studies as seeds in the Science
Citation Index (ISI Web of Knowledge) and Google Scholar
(www.scholar.google.com) to determine whether articles citing
these studies are also relevant.
Wewill handsearch abstract books ofmeetings of the International
Gynaecological Cancer Society, the European Society of Gynae-
cological Oncology and the Society of Gynecologic Oncologists
from 2000 to latest edition to identify unpublished studies.
Where necessary, we will contact themain investigators of relevant
ongoing studies for further information.
If necessary, we will also contact authors of relevant studies to ask
if they know of further data which may or may not have been
published.
Data collection and analysis
Selection of studies
We will download all titles and abstracts retrieved by electronic
searching to the referencemanagement database Endnote.We will
remove duplicates and two review authors (SR, NB) will indepen-
dently examine the remaining references. We will exclude those
studies which clearly do not meet the inclusion criteria, and obtain
copies of the full text of potentially relevant references. Two re-
view authors (SR, NB) will assess the eligibility of retrieved papers
independently.We will resolve disagreements, if possible, between
SR and NB, and, if necessary, involve a third review author ( NR,
AK, or RN). We will document reasons for exclusion.
Data extraction and management
We will extract data on the following items.
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• Author, year of publication and journal (including
language).
• Country.
• Settings.
• Inclusion and exclusion criteria.
• Study design.
• Study population.
• Number of patients.
• Definition of cervical pathology (by punch biopsy, loop
biopsy etc).
• Any triage or add-on tests done in addition to the index test.
• Experience of the operator.
• Cervical cancer details:
◦ FIGO stage;
◦ size of tumour;
◦ histological cell type;
◦ lymphovascular space involvement;
◦ previous treatment details such as loop biopsy, laser
treatment etc.
• Reference standard and performance of the reference
standard:
◦ laparoscopic or open;
◦ lymph node yield (and site);
◦ histological assessment method.
• Performance of the index test:
◦ for sentinel lymph node biopsy:
⋄ tracer substance used, amount and dilution;
⋄ method of application;
⋄ timing of application;
⋄ method of detection;
⋄ histological assessment method.
• Reporting of results:
◦ sentinel lymph node detection rate for unilateral and
bilateral nodes;
◦ in false-negative cases, are the positive nodes by
reference standard on the side where there is failure to detect
sentinel nodes?
◦ any adverse effect arising from the index test;
◦ any adverse effect arising from the reference standard.
• QUADAS-2 items (see below).
• Data for two-by-two table.
Two review authors (SR, NB) will extract data independently onto
a data abstraction spreadsheet specially designed for the review.We
will resolve differences between review authors by discussion or by
appeal to a third review author (NR,AKM, or RN) if necessary.We
will use two primary diagnostic studies to pilot the data abstraction
spreadsheet (including the quality assessment).
Assessment of methodological quality
Two review authors (SR and NB) will independently perform the
quality assessment. In case of disagreement, a consensus meeting
will be held. In case of persisting disagreement, we will refer the
issue to a third review author (NR, AKM, RN or KH). We will
assess study quality using the QUADAS-2 list (Whiting 2011).
We will report the results in detail in tabular and graphical form,
and summarise them in the text. We will report methodological
quality graphically by showing the percentage of studies that did
or did not fulfil each item. We will also produce tables showing
the results of each quality item for all individual studies.
We will assess the quality items derived from the QUADAS-2
tool using the methodology stated in Table 2. The QUADAS-
2 tool, tailored specifically for use in this review omits the core
quality questions “was a case-control design avoided?” and “if a
threshold was used, was it pre-specified?”. These quality items
are of limited applicability to this review due to the proposed
inclusion of all study designs prior to quality assessment and the
dichotomous nature of the index test and reference standard result.
Additional QUADAS-2 quality questions were included within
the index test domain: “ Did the study provide clear information
about which cases were considered to be a ’failure to detect sentinel
nodes’?” and “Had test operators had appropriate training?”. These
signalling questions represent important quality assessments for
the performance and interpretation of the index test result.
Statistical analysis and data synthesis
We will input data from two-by-two tables into Review Manager
2014 (5.3.5) for the calculations of sensitivity and specificity for
each study. We will present individual study results graphically by
plotting estimates of sensitivities and specificities in receiver op-
erating characteristic (ROC) space. If more than one threshold is
reported, we will choose the two-by-two table for the threshold
most widely reported in the included studies to incorporate in the
meta-analysis. We will use the statistical package Stata 14.1 (Col-
lege Station, TX: StataCorp, 2015) to meta-analyse pairs of sen-
sitivity and specificity using a bivariate random-effects approach
(Reitsma 2005). As we anticipate little variation in thresholds be-
tween studies (since the histological confirmation of the presence
or absence of lymph node metastases yields a dichotomous result),
we will calculate summary estimates of sensitivity and specificity,
while correctly dealing with any correlation that might exist be-
tween sensitivity and specificity.
Co-variates can be incorporated in the bivariate model in order
to examine the effect of potential sources of heterogeneity on sen-
sitivity and specificity. The results of the bivariate model will be
used to calculate likelihood ratios. To illustrate the findings, the
negative predictive value will be presented for a range of plausible
values of the prevalence of pelvic lymph node involvement; e.g. the
median and inter-quartile range of prevalence in included studies.
It is not anticipated that a false-positive result will be encountered
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as a positive result in the index test is regarded as a true-positive
result, even in the case where the reference test yields a negative
result. This arises from the assumption that a positive sentinel
lymph node would have been included in the lymphadenectomy
specimen (reference test) had the sentinel lymph node procedure
(index test) not been carried out. Therefore, positive predictive
values will not be calculated.
We will treat extra-pelvic sentinel node involvement (e.g. in the
para-aortic region) in the same way as for pelvic sentinel nodes,
i.e. removed and sent for histological assessment. Therefore, we
will include extra-pelvic sentinel nodes in the statistical analysis as
part of the overall sentinel node yield.
Investigations of heterogeneity
We will investigate heterogeneity by visual examination of forest
plots of sensitivities and specificities and through a visual examina-
tion of the ROC plot of the raw data. We will use bivariate models
to estimate imprecision by which sensitivity and specificity have
been measured within each study and variation beyond chance in
sensitivity and specificity between studies. We expect the results
of the index test to vary according to (i) the sentinel node proce-
dure (use of radioactive tracer, blue dye, ICG or a combination
of these), and (ii) whether the approach was open laparoscopic
or robotic, (iii) whether ultra-staging techniques were used in the
histological analysis of the sentinel lymph nodes.
We will investigate this by including these factors as a co-variate
in meta-regression in Stata 14.1 (College Station, TX: StataCorp,
2015), where we will test for differences between groups and ob-
tain relative measures of test accuracy such as relative diagnostic
odds ratios. We will therefore interpret our findings in the light
of possible heterogeneity between different methods of detection
and between different subgroups of patients as specified above (see
Secondary objectives). Any unexplained variability between stud-
ies will be interpreted using clinical judgement.
Sensitivity analyses
If sufficient data are available, we will explore possible sources of
bias by undertaking sensitivity analyses based on the overall quality
assessment (QUADAS-2).We will omit studies that did not satisfy
quality criteria and scored ’no’ or ’unclear’ for all QUADAS-2
domains in sensitivity analyses. If permitted by the variability of
included studies, we will also conduct sensitivity analysis based
on the type of study design, for example whether retrospective or
prospective.
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A D D I T I O N A L T A B L E S
Table 1. FIGO stage classifications
FIGO classification for cervical cancer
STAGE CHARACTERISTICS
I The carcinoma is strictly confined to the cervix (extension to the corpus should be disregarded)
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Table 1. FIGO stage classifications (Continued)
IA Invasive cancer identified onlymicroscopically. All gross lesions, evenwith superficial invasion, are stage IB cancers. Invasion
is limited to a measured stromal invasion with a maximal depth of 5.0 mm and a horizontal extension of not > 7.0 mm.
Depth of invasion should not be > 5.0 mm taken from the base of the epithelium, either surface or glandular, from which
it originates. Vascular space involvement, either venous or lymphatic, should not alter the staging
IA1 Measured stromal invasion of not > 3.0 mm in depth and extension of not > 7.0 mm
IA2 Measured stromal invasion of > 3.0 mm and not > 5.0 mm with an extension of not > 7.0 mm
IB Clinical lesions confined to the cervix or preclinical lesions > IA
IB1 Clinical lesions not > 4 cm in size.
IB2 Clinical lesions > 4 cm in size.
II The carcinoma extends beyond the cervix, but has not extended onto the pelvic wall; the carcinoma involves the vagina,
but not as far as the lower third
IIA No obvious parametrial involvement.
IIB With parametrial involvement.
III The carcinoma has extended onto the pelvic wall; on rectal examination there is no cancer-free space between the tumour
and the pelvic wall; the tumour involves the lower third of the vagina; all cases with a hydronephrosis or non-functioning
kidney should be included, unless they are known to be due to other causes
IIIA No extension onto the pelvic wall, but involvement of the lower third of the vagina
IIIB Extension onto the pelvic wall or hydronephrosis or nonfunctioning kidney
IV The carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder or rectum
IVA Spread of the growth to adjacent organs.
IVB Spread to distant organs.
Table 2. QUADAS-2 classifications
Domain Signalling
question
Signalling
question
Signalling
question
Signalling
question
Signalling
question
Risk of bias Concerns for
applicability
1. Patient se-
lection
1. Was a
consecutive or
random sam-
ple of patients
enrolled?
2. Did the
study avoid in-
appropriate
exclusions?
- - - Could the se-
lection of pa-
tients have in-
troduced bias?
Is there con-
cern that the
included pa-
tients are not
representa-
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Table 2. QUADAS-2 classifications (Continued)
tive of the pa-
tients who will
receive the test
in practice?
Yes: The study
enrolled ran-
domly sam-
pled or con-
sec-
utive patients
with clinically
deter-
mined FIGO
stage 1A2
to IIA cervical
cancer
No: The study
en-
rolled selected
patients.
Unclear: This
was not clear
from the re-
port.
Yes: All pa-
tients
with clinically
deter-
mined FIGO
stage 1A2 to
IIA
cervical cancer
were included
in the analysis
No: Patients
were excluded
following ad-
ditional triage
tests such as
computed to-
mography or
magnetic reso-
nance scan
imaging
Unclear: This
was not clear
from the re-
port.
- - - Low risk:
’yes’ for all sig-
nalling ques-
tions.
High risk: ’no’
or ’unclear’ for
sig-
nalling ques-
tion 1 or ’no’
for signalling
question 2
Unclear: ’un-
clear for sig-
nalling ques-
tion 2.
Low concern:
the selected
patients repre-
sent the pa-
tients
in whom the
tests will be
used in clinical
practice
(please see di-
agnostic path-
way, Figure 1)
High concern:
patient selec-
tion was per-
formed
in such a way
that the in-
cluded partici-
pants did not
rep-
resent patients
in whom the
tests will be
used in clinical
practice
2. Index
Test (Sentinel
node
detection and
analysis)
1.Were the in-
dex test results
interpreted
without
knowledge of
the results of
the
reference stan-
dard? (Refer-
ence standard
results
blinded)
2.
Did the study
provide a clear
definition of
what was con-
sidered to be a
“positive” and
result?
3. Did
the study pro-
vide clear in-
formation
about which
cases were
considered to
be a “failure to
detect sentinel
nodes”?
4.Had test op-
erators had ap-
propriate
training?
- Could the
conduct or in-
terpretation of
the index test
have intro-
duced bias?
Is there con-
cern that the
index test, its
conduct or in-
terpre-
tation differs
from the re-
view question?
Yes: his-
tological anal-
ysis of sentinel
node was car-
Yes: clear def-
inition for di-
agnosing sen-
Yes: clear defi-
nition of “fail-
ure to
Yes: clear in-
formation
regarding test
- Low risk:
’yes’ for all sig-
nalling ques-
Low concern:
the index test
is conducted
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Table 2. QUADAS-2 classifications (Continued)
ried out with-
out the knowl-
edge of
the histologi-
cal analysis of
the pelvic lym-
phadenec-
tomy
specimen
No: his-
tological anal-
ysis of sentinel
node was car-
ried out with
the knowledge
of the histo-
logical analysis
of the pelvic
lymphadenec-
tomy
specimen
Unclear: it is
unclear
whether histo-
logical analy-
sis of sentinel
node was car-
ried out with
or without the
knowledge of
the histologi-
cal analysis of
the pelvic lym-
phadenec-
tomy
specimen
tinel lymph
node metasta-
sis is given
No:
criteria for di-
agnosis of sen-
tinel lymph
node metas-
tases were not
pre-specified
Un-
clear: insuffi-
cient informa-
tion regarding
whether crite-
ria used were
specified be-
fore the study
was started
detect sentinel
nodes” is given
No: no clear
defini-
tion of “failure
to detect sen-
tinel nodes” is
given
Un-
clear: Insuffi-
cient informa-
tion regarding
the criteria
used to deter-
mine “failure
to detect sen-
tinel nodes” is
specified
operator train-
ing is given
No: test oper-
ator training is
not detailed
Unclear:
insufficient in-
formation
regarding test
operator train-
ing is given
tions.
High risk: ’no’
or ’unclear’ for
any one of sig-
nalling ques-
tions 1, 2 or 3
Unclear: ’no’
or ’unclear’ for
signalling
question 4
and inter-
preted in the
way it is likely
to be used in
clinical prac-
tice
High concern:
the conduct or
interpreta-
tion of the in-
dex test differs
from the way
it is likely to be
used in clinical
practice
3. Refer-
ence standard
(Pelvic lymph
node
analysis)
1. Is the refer-
ence standard
likely to cor-
rectly classify
the target con-
dition
2. Were the
reference stan-
dard results in-
terpreted
without
knowledge of
the results of
the index test?
(Index test re-
sults blinded)
3.
Did the study
provide a clear
definition of
what was con-
sidered to be
a “positive” re-
sult?
- - Could the ref-
er-
ence standard,
its conduct, or
its interpreta-
tion have in-
troduced bias?
Are there con-
cerns that
the target con-
dition as de-
fined by the
reference stan-
dard does not
match the re-
view question?
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Table 2. QUADAS-2 classifications (Continued)
Yes: all the pa-
tients received
standard
pelvic
lymphadenec-
tomy
No: some
or no patients
received stan-
dard pelvic
lymphadenec-
tomy
Unclear: sur-
gical extent of
lymphadenec-
tomy
is not reported
or could not
be clearly dis-
tinguished
Yes: histologi-
cal analysis of
the pelvic lym-
phadenec-
tomy spec-
imen was car-
ried out with-
out the knowl-
edge of
the histologi-
cal analysis of
sentinel node
No: histologi-
cal analysis of
the pelvic lym-
phadenec-
tomy spec-
imen was car-
ried out with
the knowledge
of the histo-
logical analy-
sis of sentinel
node
Un-
clear: it is un-
clear whether
the histologi-
cal analysis of
the pelvic lym-
phadenec-
tomy spec-
imen was car-
ried out with
or without the
knowledge
of histological
analysis of sen-
tinel node
Yes: clear def-
inition for di-
ag-
nosing lymph
node metasta-
sis is given
No: cri-
teria for diag-
nosis of lymph
node metas-
tases were not
pre-specified
Un-
clear: insuffi-
cient informa-
tion regarding
whether crite-
ria used were
specified be-
fore the study
was started
- - Low risk:
’yes’ for all sig-
nalling ques-
tions.
High risk: ’no’
for signalling
questions 1 or
2. ’No’ or ’un-
clear’ for sig-
nalling ques-
tion 3
Unclear: ’un-
clear for sig-
nalling ques-
tions 1 or 2.
Low concern:
the
reference stan-
dard is con-
ducted and in-
terpreted
in the way it is
used in clinical
practice
High concern:
the conduct or
interpreta-
tion of the in-
dex test differs
from the way
it is used in
clinical prac-
tice
4. Flow and
Timing
1. Was there
an appropriate
interval
between index
test and refer-
ence standard?
3. Did all pa-
tients receive a
reference stan-
dard?
3. Did pa-
tients receive
the same refer-
ence standard?
4. Were
all patients in-
cluded in the
analysis?
5. Were with-
drawals from
the study ex-
plained?
Could the pa-
tient flow have
introduced
bias?
-
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Table 2. QUADAS-2 classifications (Continued)
Yes: less
than or equal
to four weeks
between index
test and refer-
ence standard
No:more than
four weeks
between index
test and refer-
ence standard
Unclear: not
reported, vari-
able or could
not be clearly
determined
Yes:
whole popula-
tion received
reference stan-
dard.
No:
reference stan-
dard not car-
ried out in the
whole popula-
tion
Unclear:
no clear in-
formation on
what propor-
tion of popu-
lation received
reference stan-
dard
Yes: all the pa-
tients received
same reference
standard re-
gardless of in-
dex test results
No: not all the
pa-
tients received
same reference
standard re-
gardless of in-
dex test result
Un-
clear: it is un-
clear whether
all the patients
received same
reference stan-
dard re-
gardless of in-
dex test results
Yes: all en-
rolled patients
were included
in the analysis.
No: not all en-
rolled patients
were included
in the analysis
Un-
clear: it is un-
clear if all en-
rolled patients
were included
in the analysis
Yes: all with-
drawals from
study were ex-
plained.
No:
not all with-
drawals from
study were ex-
plained.
Unclear: it is
not clear if all
with-
drawals were
explained.
Low risk:
’yes’ for all sig-
nalling ques-
tions.
High risk: ’no’
for any one of
signalling
questions 1
to 5. ’Unclear’
for signalling
questions 4 or
5
Unclear: ’un-
clear’ for sig-
nalling ques-
tions 1, 2 or 3
-
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Lymph Nodes/
2. (lymph* adj (node* or nodal)).ti,ab.
3. (lymph* adj3 (mapping or spread* or staging)).ti,ab.
4. lymphadenopath*.ti,ab.
5. or/1-4
6. Pelvis/
7. (pelvic or pelvis).ti,ab.
8. Cervix Uteri/
9. (cervix or cervical or cervico*).ti,ab.
10. or/6-9
11. 5 and 10
12. Lymphatic Metastasis/ or (lymph* adj3 (metasta* or micrometasta*)).ti,ab.
13. 12 and 10
14. (neoplas* or cancer* or carcinoma* or malignan* or metasta* or micrometasta* or carcinogen* or adenocarcinoma* or
carcinosarcoma* or adenosquamous).ti,ab.
15. Neoplasm Staging/ or Neoplasm Invasiveness/ or Neoplasm Micrometastasis/
16. 14 or 15
14Sentinel node biopsy for diagnosis of pelvic lymph node involvement in early stage cervical cancer (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17. 16 and 11
18. Uterine Cervical Neoplasms/
19. exp Uterine Cervical Dysplasia/
20. Cervical Intraepithelial Neoplasia/
21. or/18-20
22. 21 and (5 or 12)
23. 22 or 17 or 13
24. Sentinel Lymph Node Biopsy/
25. (sentin?l adj3 node*).ti,ab.
26. (lymphoscintigraph* or lymphoscintigram*).ti,ab.
27. Lymphography/
28. scintiphotograph*.ti,ab.
29. (scintigraph* or scintigram*).ti,ab.
30. (gamma camera adj imag*).ti,ab.
31. (radioisotope* adj scan*).ti,ab.
32. gamma probe.ti,ab.
33. (radioactive adj3 (tracer* or isotope*)).ti,ab.
34. (near infrared adj3 (fluorescen* or imag* or endoscop* or spectroscop*)).ti,ab.
35. (NIR adj3 (fluorescen* or imag* or endoscop* or spectroscop*)).ti,ab.
36. Spectroscopy, Near-Infrared/
37. Indocyanine Green/
38. (Technetium or Tc 99m or 99mTC or blue dye* or patent blue or indocyanine green or methylene blue or isosulfan or iso sulfan
or lymphazurin blue or radiocolloid or fluorescen* dye*).ti,ab,nm.
39. Technetium Tc 99m Sulfur Colloid/
40. Rosaniline Dyes/
41. Coloring Agents/
42. Methylene Blue/
43. Fluorescent Dyes/
44. Gamma Cameras/
45. or/24-44
46. 23 and 45
47. exp animals/ not humans.sh.
48. 46 not 47
Appendix 2. Embase search strategy
1 pelvis lymph node/
2 lymph node/ or sentinel lymph node/
3 (lymph* adj (node* or nodal)).ti,ab.
4 (lymph* adj3 (mapping or spread*or staging)).ti,ab.
5 lymphadenopath*.ti,ab.
6 or/2-5
7 pelvis/
8 (pelvic or pelvis).ti,ab.
9 exp Uterine Cervix/
10 (cervix or cervical or cervico*).ti,ab.
11 or/7-10
12 6 and 11
13 1 or 12
14 exp lymph node metastasis/ or (lymph* adj3 (metasta* or micrometasta*)).ti,ab.
15 14 and 11
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16 (neoplas* or cancer* or carcinoma* ormalignan* ormetasta*ormicrometasta* or carcinogen* or adenocarcinoma* or carcinosarcoma*
or adenosquamous).ti,ab.
17 Cancer Staging/ or Tumor Invasion/
18 or/16-17
19 18 and 13
20 exp uterine cervix tumor/
21 exp uterine cervix dysplasia/
22 or/20-21
23 22 and (1 or 6 or 14)
24 23 or 13 or 15
25 sentinel lymph node biopsy/ or (sentin?l adj3 node* adj3 biops*).ti,ab.
26 lymphoscintigraphy/
27 lymphography/
28 scintillation camera/ or gamma camera/
29 exp tumor scintiscanning/
30 (lymphoscintigraph* or lymphoscintigram*).ti,ab.
31 scintiphotograph*.ti,ab.
32 (scintigraph* or scintigram*).ti,ab.
33 (gamma camera adj imag*).ti,ab.
34 (radioisotope* adj scan*).ti,ab.
35 gamma probe.ti,ab.
36 (radioactive adj3 (tracer* or isotope*)).ti,ab.
37 (Technetium or Tc 99m or 99mTC or blue dye* or patent blue or indocyanine green or methylene blue or disulfine blue or isosulfan
or iso sulfan or lymphazurin blue or radiocolloid or fluorescen* dye*).ti,ab.
38 (near infrared adj3 (fluorescen* or imag* or endoscop* or spectroscop*)).ti,ab.
39 (NIR adj3 (fluorescen* or imag* or endoscop* or spectroscop*)).ti,ab.
40 Near infrared spectroscopy/ or fluorescence spectroscopy/ or fluorescence imaging/
41 indocyanine green/
42 technetium sulfur colloid tc 99m/
43 methylene blue/
44 disulfine blue/
45 fluorescent dye/
46 coloring agent/
47 fuchsine/
48 or/25-47
49 24 and 48
50 (animal.hw. or nonhuman/) not human/
51 (veterinary or animal or animals or feline or canine or tierheilkunde).jw.
52 (cat or cats or dog or dogs or beagle or beagles or rat or rats or rodent or rodents or mouse or mice or murine or rabbit or rabbits or
pig or pigs or bitch or bitches or feline or canine or swine or porcine or sheep or hamster or hamsters or cattle or bovine or monkey or
monkeys or macaque or macaques).ti.
53 or/50-52
54 49 not 53
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WH A T ’ S N E W
Date Event Description
14 November 2017 Amended Anew teamof authors updated the text of the protocol addingnew
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14 November 2017 New citation required and minor changes Update of clinical descriptive sections following local review and
revisions to DTA methods
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